New study asks patients preference on kidney cancer treatment

Share :
Published: 2 Jun 2012
Views: 4200
Dr Bernard Escudier - Institut Gustave Roussy, Paris, France

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Bernard Escudier presented results from a randomised, double-blind study of patients with metastatic kidney cancer.  


The study found that the quality of life differences patients experienced between two FDA-approved therapies were enough to demonstrate a strong preference for pazopanib over sunitinib.